What does donated diabetes data tell us about time-in-range across different age groups?

A currently-enrolling trial is investigating a new arthritis medication along with type 2 diabetes drug Victoza, aiming to preserve insulin production in people with...

The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins

Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA

Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba

Bigfoot Biomedical and Abbott partner to use “next-generation” FreeStyle Libre glucose monitoring sensor (no fingersticks needed) with Bigfoot’s automated insulin...

Novo Nordisk’s newest insulin receives EMA approval; expected to launch in the first half of 2017

How do I stay in range while sleeping?

Instead of “avoid long-term complications,” Adam Brown focuses on something more motivating and uplifting

Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits

Amalgam Rx receives FDA clearance for basal insulin dosing app, iSage Rx; available with a prescription to adjust Lantus, Levemir, Toujeo, Tresiba, and Basaglar

Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA

Ease, comfort, and actionable patterns, but some challenges with insurance coverage

Faster version of Novo Nordisk’s NovoLog approved in the US for type 1 and type 2 diabetes, launch expected as early as end of 2017

The new blood glucose meter features less expensive strips, uploads readings to smartphones, and integrates with mySugr

Learn practical tips on taking care of your feet and how to easily make them a part of daily diabetes management

Lilly’s Humalog Junior KwikPen offers 0.5 unit dose increments in prefilled, disposable device – a win for highly insulin sensitive users

Why a good night of sleep transforms Adam Brown's diabetes the next day

Training to be tested in a small group before the full launch starts in June

Full results of DEVOTE study presented at ADA 2017 show that basal insulin Tresiba reduces risk of severe hypoglycemia by 40% (by 53% overnight), in addition to being...